Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD Cosentyx® - IL-17A inhibitor Study Indication Phase Patients Primary Outcome Measures NCT04930094 (CAIN457R12301) Giant cell arteritis Phase 3 240 Arms Intervention Target Patients Read-out Milesstone(s) Publication Number of participants with sustained remission Experimental: Secukinumab 300 mg Placebo Comparator: Placebo Patients with Giant Cell Arteritis (GCA) Primary 2023 Final 2025 TBD 78 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation